Bayer Puts Spotlight On Pharma Pipeline
Emerging As A Leader In Cell And Gene Therapy
The Leverkusen-based firm has been touting the potential of its pharmaceutical pipeline which it hopes will be able to help soften the blow of patent expiries on the blockbusters Xarelto and Eylea in the next few years.
